2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1842

Pentraxin 3 Level Positively Correlated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients
Abstract Number: 1843

Single Cell Expression Quantitative Trait Loci (eQTL) Analysis of Established SLE-Risk Loci in Lupus Patient Monocytes
Abstract Number: 1844

Mesenchymal Stem Cells Ameliorate the Deficiencies in Immunomodulatory and Phagocytic Capacities of Lupus Macrophages
Abstract Number: 1845

TGF-β-Induced Tissue Fibrosis Is Abrogated in Mice Containing a Constitutive Genetic Deletion of Nox4 (Nox4 knockout)
Abstract Number: 1846

Cutaneous and Visceral Fibrosis Induced By Endothelial Cell-Specific Constitutive Activation of TGF-β1 Signaling in Mice
Abstract Number: 1847

WITHDRAWN
Abstract Number: 1848

Adenosine A2A Receptor (A2AR) Stimulates Collagen Type III Synthesis Via β-Catenin Activation in Vitro and in Vivo
Abstract Number: 1849

Fibroblast Growth Factor 9/ Fibroblast Growth Factor Receptor 3 Signaling Is Upstream of Several Profibrotic Pathways and Induces Fibroblast Activation and Tissue Fibrosis in SSc
Abstract Number: 1850

Optimization of a Murine Model to Recapitulate Dermal and Pulmonary Features of SSc
Abstract Number: 1851

The Effect of Narrow Band Ultraviolet A1 Light on Bleomycin-Induced Mouse Model of Scleroderma
Abstract Number: 1852

Decreased Expression of Sirtuin 7 By Lung Fibroblasts from Patients with Scleroderma Contributes to Elevated Collagen Production
Abstract Number: 1853

Klf5+/-;Fli1+/- Mice Recapitulate Protracted Wound Healing and Cardiac and Intestinal Involvement Associated with Systemic Sclerosis
Abstract Number: 1854

Increased Percentage of CD204/CD206 Double Positive Monocytes Correlates with Specific Lung and Skin Involvement Parameters and an “Active” Capillaroscopic Pattern of Microangiopathy in Systemic Sclerosis Patients
Abstract Number: 1855

Phosphodiesterase-5 Inhibitors Attenuate Fibrotic Phenotype and Restore Anti-Fibrotic Resopnses of Cutaneous Fibroblasts in Patients with Scleroderma
Abstract Number: 1856

Discovery of a Small Molecule Inhibitor of the Wnt Pathway (SM04755) As a Potential Topical Treatment for Scleroderma

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].